US Stock Insider Trading | Recursion disclosed one insider transaction on March 11

K-LinePoet · 2026-04-01T10:52:06+00:00

Recursion Pharmaceuticals recently disclosed insider trading information. Director Khan Najat sold 28,300 shares on March 9th at a price of $3.35, totaling approximately $94,700. The company is dedicated to using big data for drug discovery.

K-LinePoet

2026-04-01 10:52:06

Abstract generation in progress

On March 11, 2026, Recursion (RXRX) disclosed one transaction involving company insiders. Director Khan Najat sold 28,300 shares on March 9, 2026.

【Recent Insider Transactions】

Disclosure date	Position	Name	Trade date	Buy/Sell	Shares	Price per share/US$	Total amount/US$
March 11, 2026	Director	Khan Najat	March 9, 2026	Sold	28,300	3.35	94,700
March 4, 2026	Director	Borgeson Blake	March 3, 2026	Sold	170,000	3.46	588,200
February 19, 2026	Executive	Hallett David	February 17, 2026	Sold	11,900	3.49	41,600
February 19, 2026	Executive	Taylor Ben R	February 18, 2026	Sold	13,400	3.08	41,400
February 19, 2026	Director	Khan Najat	February 17, 2026	Sold	14,300	3.49	49,800
February 19, 2026	Executive	Taylor Ben R	February 17, 2026	Sold	11,900	3.49	41,600
February 19, 2026	Director	Gibson Christopher	February 19, 2026	Sold	40,000	3.46	138,400
February 19, 2026	Director	Gibson Christopher	February 17, 2026	Sold	27,300	3.49	95,200
February 10, 2026	Director	Khan Najat	February 6, 2026	Sold	10,400	3.98	41,200
February 10, 2026	Executive	Taylor Ben R	February 6, 2026	Sold	11,400	3.98	45,400

【Company Profile】

Recursion Pharmaceuticals, Inc. was first incorporated on November 4, 2013, and is incorporated in Delaware. The company is a leading clinical-stage TechBio company, decoding biology to industrialize drug discovery. At the core of the company’s mission is the Recursion Operating System (OS), a platform built across multiple technologies that enables the company to draw and navigate trillions of relationships centered on biology, chemistry, and patients across more than 50 PB of proprietary data. The company frames this integration of physical and digital components as an iterative loop: scaled “wet lab” biology and chemistry, as well as patient-centered experimental data, are organized by “dry lab” computational tools, so that therapeutic insights can be identified, validated, and translated.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.